Group 1 - The company, Jinfang Pharmaceutical-B (02595), has been included in multiple indices, including the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Index, and Hang Seng Innovative Drug Index, effective March 9, 2026 [1] - The company will also be added to the MSCI Global Small Cap Index, with the adjustment effective after the market close on February 27, 2026 [1] - Inclusion in these indices will allow the company's stock to be traded through the Hong Kong Stock Connect and Shenzhen Stock Connect, enhancing its accessibility to investors [1] Group 2 - The company is also selected for several other Hang Seng indices, such as the Hang Seng Composite Small Cap Index and the Hang Seng Healthcare Index, reflecting investor recognition of its value and growth potential [2] - The board anticipates that this inclusion will improve stock liquidity, broaden the shareholder base, and diversify the types of shareholders, contributing to the company's long-term stable development [2] - The company aims to strengthen its leading position in the RAS sector and enhance its international competitiveness in innovative drug fields, driving value creation through its R&D advantages [2]
劲方医药-B(02595)获纳入恒生指数系列及MSCI指数成份股